SEC Form 4 · accession 0001615774-18-000390
Ensysce Biosciences, Inc. · ENSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
HG Vora Capital Management, LLC
10% Owner
Period of report
Dec 1, 2017
Accepted (ET)
Jan 17, 2018 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001716947
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 1, 2017 | P | 1,000,000 | $10.00 | A | 3,837,500 | I | See Footnote |
| Common StockF2,F1 | Jan 15, 2018 | J | 375,000 | $0.00 | D | 3,462,500 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities owned directly by HG Vora Special Opportunities Master Fund, Ltd. ("HG Vora Special Opportunities"). HG Vora Capital Management, LLC ("HG Vora Capital) is a registered investment adviser under the Investment Advisers Act of 1940, as amended, and acts as an investment adviser to certain investment entities. HG Vora Capital, as investment manager of HG Vora Special Opportunities, may be deemed to beneficially own the securities owned directly by HG Vora Special Opportunities.
- F2As contemplated by the securities subscription agreement between HG Vora Special Opportunities and the Company, 375,000 shares held by HG Vora Special Opportunities were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.